- Home
- VELO vs AUTL Comparison
VELO vs AUTL Comparison
Compare VELO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VELO | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | 134 | 752 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.9M | 428.5M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | VELO | AUTL |
|---|---|---|
| Price | $13.60 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $8.50 |
| AVG Volume (30 Days) | ★ 5.5M | 983.2K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $42.22 | $80.32 |
| Revenue Next Year | $50.08 | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $2.87 | $1.18 |
| 52 Week High | $31.75 | $2.70 |
Technical Indicators
Market Signals| Indicator | VELO | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 59.12 |
| Support Level | $12.72 | $1.38 |
| Resistance Level | $16.35 | $1.73 |
| Average True Range (ATR) | 2.70 | 0.10 |
| MACD | -1.05 | 0.01 |
| Stochastic Oscillator | 4.02 | 88.68 |
Price Performance
Historical ComparisonAbout VELO Velo3D Inc.
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.